ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting

    Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover

    Anne C. Bay-Jensen1, Inger Byrjalsen2, Andrew Kenwright3, Thierry Sornasse4, Claus Christiansen5 and Morten Asser Karsdal6, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Research & Development, Nordic Bioscience, Herlev, Denmark, 3Roche, Welwyn Garden City, United Kingdom, 4Genentech, South San Francisco, 5CCBR, Ballerup, Denmark, 6Nordic Bioscience A/S, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
  • Abstract Number: 1333 • 2012 ACR/ARHP Annual Meeting

    The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)

    Atsushi Ihata1, Hiroyuki Hagiyama2, Shouhei Nagaoka3, Junichi Obata4, Kiyomitsu Miyachi5, Hidehiro Yamada6, Shunsei Hirohata7, Norihiko Koido8, Masaomi Yamasaki9, Kenichi Miyagi10, Shigeru Ohno11, Daiga Kishimoto1, Reikou Watanabe1, Takeaki Uehara12, Kaoru Takase1, Maasa Hama1, Ryusuke Yoshimi1, Atsuhisa Ueda1, Mitsuhiro Takeno1 and Yoshiaki Ishigatsubo1, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, 3Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, 4Hikarichuo Clinic, Kawasaki, Japan, 5Keigu Clinic, Kawasaki, Japan, 6Internal Medicine, St. Marianna University, Kawasaki, Japan, 7Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 8Kawasaki Rheumatism & Internal Medecine Clinic, Kawasaki, 9Internal Medicine, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, 10Miyagi Naika Clinic, Yokohama, 11Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 12Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan

    Background/Purpose: An administration of tocilizumab (TCZ) rapidly suppresses inflammatory markers such as CRP and ESR, which makes the diagnosis of infection difficult. There is a…
  • Abstract Number: 1335 • 2012 ACR/ARHP Annual Meeting

    Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy

    Patrick Durez1, Geneviève Depresseux2, Marie Avaux2, Adrien Nzeusseu Toukap3, Bernard Lauwerys3, Laurent Meric de Bellefon2, Maria S. Stoenoiu2 and Frédéric A. Houssiau4, 1Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, 3Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 4Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Tocilizumab (TCZ), as monotherapy and in combination with methotrexate (MTX), has been shown to be efficacious for rheumatoid arthritis patients with insufficient response to…
  • Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting

    IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis

    Masayasu Kitano1, Sachie Kitano1, Chieri Sato1, Kazuyuki Fujita1, Takahiro Yoshikawa1, Yuki Katashima1, Masahiro Sekiguchi1, Naoto Azuma1, Naoaki Hashimoto, Shinichiro Tsunoda1, Kiyoshi Matsui1 and Hajime Sano1, 1Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan

    Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…
  • Abstract Number: 1243 • 2012 ACR/ARHP Annual Meeting

    Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms

    Hitomi Kobayashi1, Isamu Yokoe2, Hiroshi Sato1 and Yasuyuki Kobayashi3, 1Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 2Nihon University School of Medicine, Tokyo, Japan, 3Radiology, St.Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to…
  • Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting

    IL-6 and IL-21 in Rheumatoid Arthritis

    Gustavo Carbone1, Augusta Wilson1, Sean Diehl2, Janice Bunn3, Sheldon Cooper4 and Mercedes Rincon5, 1Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, 2Immunobiology, University of Vermont College of Medicine, 3Mathematics and Statistics, University of Vermont, Burlington, VT, 4Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, 5Immunobiology, University of Vermont College of Medicine, Burlington, VT

    Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology